Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENEMID vs PROBALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Inhibits xanthine oxidase, reducing uric acid production.
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
Gout,Hyperuricemia,Prevention of tumor lysis syndrome
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
500 mg orally once daily.
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (Cr Cl <30 m L/min) requiring dose adjustment.
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Primarily hepatic via CYP450; produces active metabolites.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for 15-25% with the remainder as metabolites.
Approximately 85-95% bound primarily to albumin
90-95% bound primarily to albumin and alpha-1-acid glycoprotein.
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
0.15-0.25 L/kg; reflects distribution mainly into extracellular fluid with limited tissue penetration.
Oral: >90%
Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); Intravenous: 100%.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
Cr Cl 30-50 m L/min: 250 mg daily; Cr Cl <30 m L/min: 125 mg daily; hemodialysis: 125 mg after dialysis.
No specific guidelines; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: not recommended.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
10 mg/kg orally once daily, max 500 mg; for children <2 years: 5 mg/kg once daily.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
Start at 250 mg daily; monitor renal function and adjust based on Cr Cl.
No FDA black box warning.
None
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Acute gout flares may occur initially,Hypersensitivity reactions including Stevens-Johnson syndrome,Renal impairment requires dose adjustment
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Hypersensitivity to probalan,Concurrent use with azathioprine or mercaptopurine
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
High-purine foods (organ meats, anchovies, sardines) may increase uric acid; limit intake. Alcohol, especially beer, reduces uricosuric effect and increases uric acid; avoid or limit. Aspirin (anti-inflammatory doses) and some diuretics (thiazides) can reduce efficacy; avoid concurrent use.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with third-trimester exposure due to inhibition of fetal renal clearance. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk.
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
Probenecid is excreted into breast milk in small amounts. M/P ratio is approximately 0.1. Infant exposure is negligible, but caution is advised due to potential for kernicterus in jaundiced infants. Consider discontinuing breastfeeding if infant is G6PD deficient.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
No standard dose adjustment recommended. Pregnancy increases renal clearance and volume of distribution, potentially reducing serum concentrations. Consider therapeutic drug monitoring if response inadequate. Avoid use in third trimester unless benefits outweigh risks.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
PROBALAN (probenecid) is a uricosuric agent used for chronic gout. Monitor serum uric acid levels; goal <6 mg/d L. Avoid in patients with creatinine clearance <50 m L/min or history of uric acid stones. Ensure adequate hydration (≥2 L/day) to prevent nephrolithiasis. Alkalinize urine (p H 6.5-7.0) with potassium citrate if needed. Contraindicated with aspirin >1 g/day due to decreased uricosuric effect. Not effective during acute gout attacks; initiate after inflammation subsides.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2 liters of water daily to prevent kidney stones.,Avoid aspirin or aspirin-containing products; use acetaminophen for pain.,Report rash, fever, or painful urination immediately.,May take several months to achieve full effect; do not stop suddenly.
No interactions on record
No interactions on record
Common clinical questions about BENEMID vs PROBALAN, answered by our medical review team.
BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. PROBALAN is a Uricosuric Agent that works by Inhibits xanthine oxidase, reducing uric acid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENEMID and PROBALAN depend on the specific clinical indication. These are both Uricosuric Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. The standard adult dose of PROBALAN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENEMID and PROBALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. PROBALAN is classified as Category C. PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.